BR112019006041A2 - métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma - Google Patents

métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma

Info

Publication number
BR112019006041A2
BR112019006041A2 BR112019006041A BR112019006041A BR112019006041A2 BR 112019006041 A2 BR112019006041 A2 BR 112019006041A2 BR 112019006041 A BR112019006041 A BR 112019006041A BR 112019006041 A BR112019006041 A BR 112019006041A BR 112019006041 A2 BR112019006041 A2 BR 112019006041A2
Authority
BR
Brazil
Prior art keywords
immune checkpoint
methods
block therapy
enhancing microbial
checkpoint block
Prior art date
Application number
BR112019006041A
Other languages
English (en)
Inventor
Wargo Jennifer
Gopalakrishnan Vancheswaran
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61760978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112019006041(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112019006041A2 publication Critical patent/BR112019006041A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

a presente invenção fornece métodos e composições para o tratamento do câncer por modulação do microbioma para aumentar a eficácia do bloqueio do ponto de verificação imunológico. o microbioma pode ser modulado pela administração de butirato ou de bactérias produtoras de butirato. são também fornecidos na presente invenção métodos de determinação de uma resposta a um inibidor do ponto de verificação imunológico identificando se um indivíduo possui um perfil microbiano favorável.
BR112019006041A 2016-09-27 2017-09-27 métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma BR112019006041A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662400372P 2016-09-27 2016-09-27
US201762508885P 2017-05-19 2017-05-19
US201762557566P 2017-09-12 2017-09-12
PCT/US2017/053717 WO2018064165A2 (en) 2016-09-27 2017-09-27 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

Publications (1)

Publication Number Publication Date
BR112019006041A2 true BR112019006041A2 (pt) 2019-09-03

Family

ID=61760978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019006041A BR112019006041A2 (pt) 2016-09-27 2017-09-27 métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma

Country Status (10)

Country Link
US (3) US11395838B2 (pt)
EP (1) EP3518946A4 (pt)
JP (2) JP7542946B2 (pt)
KR (3) KR102708641B1 (pt)
CN (2) CN116196425A (pt)
AU (1) AU2017335732A1 (pt)
BR (1) BR112019006041A2 (pt)
CA (1) CA3038076A1 (pt)
MX (2) MX2019003447A (pt)
WO (1) WO2018064165A2 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ738068A (en) 2015-05-06 2019-07-26 Snipr Tech Ltd Altering microbial populations & modifying microbiota
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
BR112019006041A2 (pt) 2016-09-27 2019-09-03 Univ Texas métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
WO2018094190A2 (en) * 2016-11-18 2018-05-24 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
KR102713874B1 (ko) * 2017-08-11 2024-10-10 제넨테크, 인크. 항-cd8 항체 및 이의 용도
WO2019165285A1 (en) * 2018-02-23 2019-08-29 Crestovo Holdings Llc Microbiome related immunotherapies
US20210038654A1 (en) * 2018-03-16 2021-02-11 Persephone Biosciences Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
EP4066851A1 (en) 2018-03-25 2022-10-05 SNIPR Biome ApS. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP4056192A1 (en) * 2018-05-11 2022-09-14 4D Pharma Research Limited Compositions comprising bacterial strains
US11759485B2 (en) * 2018-06-14 2023-09-19 Meiji Co., Ltd. Composition for enhancing immune checkpoint blockade therapy
CN110638838B (zh) * 2018-06-26 2021-07-06 瑞微（深圳）生物科技有限公司 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用
EP3854224A4 (en) * 2018-09-21 2022-04-27 Nihon Sizen Hakkoh Co., Ltd. IMMUNE CHECKPOINT INHIBITOR
CA3116130A1 (en) * 2018-10-13 2020-04-16 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk for poor car t cell therapy response
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
EP3866819A1 (en) * 2018-10-15 2021-08-25 PharmaBiome AG A method of manufacturing a consortium of bacterial strains
WO2020079021A1 (en) * 2018-10-15 2020-04-23 Pharmabiome Ag Consortia of living bacteria useful for treatment of cancer related diseases, particularly graft versus host disease
WO2020106983A1 (en) * 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020118232A1 (en) * 2018-12-07 2020-06-11 President And Fellows Of Harvard College Identification of gut bacteria that promote an anti-tumor response to immunotherapy
WO2020149026A1 (ja) * 2019-01-04 2020-07-23 国立大学法人京都大学 Ｐｄ－１シグナル阻害剤含有薬剤による治療有効性の予測及び／又は判定マーカー
GB201900754D0 (en) * 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
CN109680085B (zh) * 2019-01-22 2021-01-29 深圳未知君生物科技有限公司 基于肠道微生物信息预测治疗响应性的模型
WO2020205927A2 (en) * 2019-04-01 2020-10-08 Board Of Regents, The University Of Texas System Tumor microbiome signature and therapeutic use of fecal microbiota transplantation on pancreatic cancer patients
CN109966320B (zh) * 2019-04-26 2022-08-05 青岛东海药业有限公司 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
KR20200134883A (ko) 2019-05-24 2020-12-02 주식회사 엘지화학 전고체전지용 음극의 제조방법
US20220370553A1 (en) * 2019-07-31 2022-11-24 Sanford Burnham Prebys Medical Discovery Institute Prebiotic-induced anti-tumor immunity
US20220339212A1 (en) 2019-08-28 2022-10-27 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
CN114728062A (zh) * 2019-09-23 2022-07-08 密执安大学评议会 用于提高免疫疗法和疫苗功效的组合物和方法
KR102485269B1 (ko) * 2019-10-18 2023-01-06 주식회사 지놈앤컴퍼니 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물
CN115698257A (zh) * 2019-11-01 2023-02-03 Uti有限合伙公司 利用微生物群和代谢物的力量治疗癌症
EP4076482A4 (en) * 2019-12-20 2024-02-14 Persephone Biosciences, Inc. COMPOSITIONS FOR MODULATING INTESTINAL MICROFLORA POPULATIONS, IMPROVING THE EFFECTIVENESS OF DRUGS AND TREATING CANCER, AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
IL271775A (en) * 2019-12-31 2021-06-30 Biomica Ltd A microbial consortium and its uses
KR102472648B1 (ko) * 2020-01-02 2022-12-01 인제대학교 산학협력단 염증성 장질환 환자의 미생물 군집 평가 방법
WO2021141828A1 (en) * 2020-01-10 2021-07-15 Assembly Biosciences, Inc. Compositions comprising bacterial species and methods related thereto
KR20210101620A (ko) * 2020-02-10 2021-08-19 주식회사 천랩 패칼리박테리움 속 균주를 이용한 항암 치료
AU2021220620A1 (en) * 2020-02-12 2022-08-18 Universität Zürich A bacterial composition for the treatment of cancer
CA3177351A1 (en) * 2020-02-18 2021-08-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk of poor cancer survival
CN111110852A (zh) * 2020-02-27 2020-05-08 上海上药信谊药厂有限公司 抗肿瘤组合物
WO2021176036A1 (en) * 2020-03-06 2021-09-10 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie E. V. Hans-Knöll-Institut (Hki) Method for the modulation of cancer treatment based on analyzing the gut microbiome
US20220290226A1 (en) * 2020-03-20 2022-09-15 Zoe Global Limited Microbiome fingerprints, dietary fingerprints, and microbiome ancestry, and methods of their use
JP2023522716A (ja) * 2020-04-21 2023-05-31 シティ・オブ・ホープ がんの治療のためのクロストリジウム・ブチリカムを含む組成物および方法
CN111494637A (zh) * 2020-04-28 2020-08-07 东华大学 一种抗肿瘤联合制剂及其应用
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CN113106163B (zh) * 2020-05-27 2024-06-04 微度(苏州)生物科技有限公司 一种用于结直肠癌早期诊断的生物标志物组合物及应用
CA3202362A1 (en) * 2020-09-30 2022-04-07 National Cancer Center Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium
US20230381247A1 (en) * 2020-10-21 2023-11-30 Gusto Global, Llc Microbial-based compositions for systemic inflammation control
CN112458031B (zh) * 2020-12-23 2022-04-29 江南大学 一株源自白酒酿造窖泥的产乳酸型己酸菌及其应用
WO2022159569A1 (en) * 2021-01-20 2022-07-28 Memorial Sloan Kettering Cancer Center Peripheral blood phenotype linked to outcomes after immunotherapy treatment
CN112877268A (zh) * 2021-04-22 2021-06-01 上海耀旦生物科技有限公司 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用
CN115998771A (zh) * 2021-07-16 2023-04-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种细菌在制备免疫检查点抑制剂的增效剂中的应用
CN114425080B (zh) * 2022-01-12 2023-08-29 广州知易生物科技有限公司 脆弱拟杆菌与pd-1或pd-l1抗体联合用药治疗生殖泌尿系统癌症的应用
CN114344338B (zh) * 2022-01-12 2023-08-04 广州知易生物科技有限公司 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用
CN114344340B (zh) * 2022-01-12 2023-07-25 广州知易生物科技有限公司 脆弱拟杆菌与pd-1及pd-l1抗体联合用药治疗呼吸系统肿瘤中的应用
CN114306616B (zh) * 2022-01-12 2023-04-28 广州知易生物科技有限公司 脆弱拟杆菌和免疫检查点抑制剂的新应用
WO2023140721A1 (ko) * 2022-01-21 2023-07-27 가톨릭대학교 산학협력단 위암 환자 장내균총 분석을 통한 면역 저하 진단과 장내균총을 이용한 테라그노시스 조성물
KR102627070B1 (ko) * 2022-06-27 2024-01-23 한국과학기술원 미생물, 및 면역관문 억제제를 유효성분으로 포함하는,고 당분 환경에서의 뇌종양 예방 또는 치료용 조성물
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
NL2032642B1 (en) * 2022-07-29 2024-02-06 Academisch Ziekenhuis Leiden Improvement of muscle mass and strength
WO2024102452A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Hepatoprotective probiotic compositions
CN116042827B (zh) * 2022-12-07 2023-12-22 臻傲生物科技检测(深圳)有限公司 预测结直肠癌风险的新型微生物标志物
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
KR20240142662A (ko) * 2023-03-21 2024-10-02 재단법인 아산사회복지재단 신규한 프레보텔라 멀대 이뮤노액티스 균주 및 이의 용도
CN117363511B (zh) * 2023-08-18 2024-09-03 四川大学 一种可改善阴道炎疾病的融合魏斯氏菌及其应用
CN116785277B (zh) * 2023-08-23 2023-11-07 中国农业大学 染料木黄酮在制备调控肠道菌丰度的制剂中的应用
CN117344018B (zh) * 2023-09-28 2024-04-30 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一组用于预测鼻咽癌复发转移风险的瘤内菌标志物及其应用
CN117625500B (zh) * 2024-01-24 2024-04-02 中山大学 一种胃梭菌及其应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
WO1995001994A1 (en) 1993-07-09 1995-01-19 Synergen, Inc. Recombinant ctla4 polypeptides and methods for making the same
DE4440528C2 (de) 1994-11-12 2001-02-01 Lohmann Therapie Syst Lts Implantierbare Vorrichtung zur Verabreichung von Wirkstoffen an Pflanzen
US5763488A (en) 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
ES2340745T3 (es) 1998-12-23 2010-06-08 Pfizer Inc. Anticuerpos monoclonales humanos contra ctla-4.
AU784012B2 (en) 1999-08-24 2006-01-12 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
KR101375153B1 (ko) 2003-07-02 2014-03-18 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및치료에서의 그 사용 방법
KR20060038461A (ko) 2003-07-24 2006-05-03 이나뜨 파르마 Ｎｋ 세포 강화 화합물을 사용하여 치료용 항체의 효율을높이는 방법 및 조성물
DE102004031929A1 (de) 2004-06-23 2006-01-12 Felsomat Gmbh & Co Kg Modulare Automationszelle
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
EP2604278B1 (en) 2007-01-11 2017-04-12 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
MX2010008786A (es) 2008-02-11 2010-12-01 Curetech Ltd Anticuerpos monoclonales para tratamiento de tumores.
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
WO2011008369A1 (en) 2009-06-29 2011-01-20 Illinois Tool Works Inc. Two-phase spring
CN102762593B (zh) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
WO2011026132A2 (en) 2009-08-31 2011-03-03 1/3Acamplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
EP2531589B1 (en) 2010-02-01 2017-04-05 MikrobEX Bacteriotherapy for Clostridium difficile colitis
RS61136B1 (sr) 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
EA035033B1 (ru) 2010-11-22 2020-04-20 Иннейт Фарма Са Способ лечения гематологического предракового или гематологического ракового заболеваний
MX347514B (es) 2011-05-25 2017-04-28 Innate Pharma Sa Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
EP2773651B1 (en) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US10098020B2 (en) 2012-08-03 2018-10-09 Intel Corporation Techniques for sending or receiving channel state information reports associated with a coordinated multi-point scheme
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
BR112016001420A2 (pt) 2013-08-02 2018-01-23 Aduro Biotech Holdings Europe B V combinação de agonistas de cd27 e inibição pontual imune para estimulação imune
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015066625A1 (en) 2013-11-01 2015-05-07 Washington University Methods to establish and restore normal gut microbiota function of subject in need thereof
EP2876167A1 (en) * 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015153639A1 (en) 2014-03-31 2015-10-08 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
US10300137B2 (en) 2014-04-10 2019-05-28 Riken Compositions and methods for induction of TH17 cells
WO2016063263A2 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
CN105296590B (zh) 2015-09-30 2019-04-19 上海锐翌生物科技有限公司 大肠癌标志物及其应用
WO2017172894A2 (en) * 2016-03-30 2017-10-05 The Trustees Of Columbia University In The City Of New York Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
BR112019006041A2 (pt) 2016-09-27 2019-09-03 Univ Texas métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
CN110582291A (zh) 2016-12-22 2019-12-17 古斯达威罗斯研究所 抗pd1/pd-l1/pd-l2抗体的反应性标志物和功效改善用调节剂
BR112020019863A2 (pt) 2018-03-28 2021-03-23 Seres Therapeutics, Inc. Composições do microbioma para o tratamento de câncer

Also Published As

Publication number Publication date
MX2019003447A (es) 2019-08-29
KR102708641B1 (ko) 2024-09-24
JP2020500151A (ja) 2020-01-09
US11395838B2 (en) 2022-07-26
EP3518946A2 (en) 2019-08-07
CN110267651A (zh) 2019-09-20
CN110267651B (zh) 2023-09-01
KR20190061042A (ko) 2019-06-04
KR20230066654A (ko) 2023-05-16
US20240173361A1 (en) 2024-05-30
KR102530297B1 (ko) 2023-05-10
JP2023029829A (ja) 2023-03-07
WO2018064165A3 (en) 2019-06-06
CA3038076A1 (en) 2018-04-05
EP3518946A4 (en) 2020-09-09
WO2018064165A2 (en) 2018-04-05
AU2017335732A1 (en) 2019-04-04
US20200129569A1 (en) 2020-04-30
RU2019108925A (ru) 2020-10-29
CN116196425A (zh) 2023-06-02
JP7542946B2 (ja) 2024-09-02
MX2022003895A (es) 2022-04-19
RU2019108925A3 (pt) 2021-12-20
KR20240142597A (ko) 2024-09-30
US20230109343A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
BR112019006041A2 (pt) métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
CL2019001711A1 (es) Composiciones y métodos para inhibir la acción de la arginasa.
ECSP19043710A (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
BR112018006689A2 (pt) terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
BR112016028255A2 (pt) agentes imunorreguladores
CL2017001464A1 (es) Modulación inmunológica
BR112018072986A2 (pt) anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
UY37230A (es) Moduladores de la vía de estrés integrada
UY37231A (es) Moduladores de la vía de estrés integrada
UY37228A (es) Moduladores de la vía de estrés integrada
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
BR112019005305A2 (pt) compostos espirocíclicos
BR112018004620A2 (pt) moduladores da expressão de kras
UY37229A (es) Moduladores de la vía de estrés integrada
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112018013522A2 (pt) compostos inibidores de metaloenzima
BR112015025854A2 (pt) flagelina de roseburia e modulação imunológica
WO2017007941A3 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms
BR112015023760A2 (pt) compostos e composições terapêuticas
BR112015021999A2 (pt) inibidores de indoleamina 2,3-dioxigenase (ido)
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
BR112015023207A8 (pt) composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014104-0 PROTOCOLO 870230061572 EM 13/07/2023 15:26.